INTRODUCTION
The Genetic Analysis Workshops (GAWs) began in 1982 as a collaborative effort among researchers of various disciplines to evaluate and compare statistical genetics methods. For each GAW, one or more topics are chosen that relate to current analytical and methodological issues in statistical genetics of complex phenotypes. For each workshop, sets of simulated and real data are distributed to researchers worldwide who submit the results of their analyses of these data for presentation at GAW. The workshop itself is a 2 1 2 -day meeting comparing and contrasting the many different approaches used to analyze the data. New methods are introduced, old methods are evaluated in new contexts, and diverse analytical schemes are explored on the level playing field of a common data set. More information about GAW, including details of upcoming workshops, may be found at http://www.sfbr.org/external/gaw/ welcome.html.
GAW13 was held November 11-14, 2002 , in New Orleans, Louisiana. The 117 contributions submitted to GAW13 were organized into 11 presentation groups of 6-14 papers each. Within each group, a co-author with previous GAW experience was asked to serve as group leader to facilitate group discussion, organize an oral presentation for the group, and take the lead in writing the group summary papers collected in this volume. Eight presentation groups were organized around common methodological themes: derived phenotypes, methods for longitudinal analysis, consistency of genetic analyses across time, missing data and pedigree or genotyping errors, effects of covariates, pleiotropy and multivariate analyses, data mining/neural networks/tree-based methods, and development and extension of linkage methods. The remaining three presentation groups contained papers united by a common focus on particular phenotypes: analysis of blood pressure and hypertension phenotypes, analysis of obesity/ diabetes/lipid phenotypes, and analysis of tobacco and alcohol phenotypes. Of the original 117 GAW13 contributions, 101 were published as a supplement to BMC Genetics [Almasy et al., 2003] . It is these 101 peer-reviewed, published papers that are summarized in the present volume.
Summaries have long been a part of the GAW proceedings. For many years, a single individual was charged with the Herculean task of summarizing all the GAW contributions, using a particular data set. As of GAW11, there were as many as 67 individual contributions to be summarized for a given data set, and the task was divided among pairs of individuals. With the increasing GAW participation, it also became increasingly difficult to accommodate individual oral presentation of each paper within the schedule of the workshop. For GAW12, a new format was introduced both for workshop presentations and for summary papers. Individual contributions with common themes were assigned to presentation groups that had a single oral presentation at the workshop. In the GAW12 proceedings [Wijsman et al., 2001 ], group leaders were asked to provide brief two-page introductions to the papers in their section. For GAW13, the presentation group format was retained and expanded, with more extensive collaborative interactions among group members. Groups continued to communicate after the workshop and worked together to compare, contrast, summarize, and synthesize their individual contributions, producing the group summary papers presented here.
GAW13 participants had the choice of two data sets to analyze. As has been the custom with recent GAWs, these included both simulated data and data from an actual human study. The Framingham Heart Study generously donated longitudinal family data related to cardiovascular disease risk factors, along with genotypes for a genome scan. In a twist new to GAW13, the simulated data set was designed to closely mirror the Framingham data in many respects. Both data sets are discussed below, and more detailed descriptions can be found in Cupples et al. [2003] and Daw et al. [2003] . Because the data sets were alike in many important respects and could be used to explore similar analytical problems, presentation groups were assigned without regard to the data set analyzed. Thus, some of the summary papers presented here include analyses of both the simulated data and the Framingham Heart Study data. This is the first time longitudinal family data have been available for a GAW. The longitudinal aspect of the data was one of the foci of discussion during the workshop. Issues explored included optimal ways of incorporating longitudinal data into genetic analyses, consistency of genetic analyses across time, derivation of new phenotypes from longitudinal data, and how to deal with incomplete data resulting from participants attending only a subset of the examinations. The cardiovascular risk factors in the Framingham Heart Study data also provided a major focus, with many GAW investigators concentrating on the biology and genetics of these traits. Finally, many groups used the data crosssectionally to evaluate the performance of linkage methods and methods for obtaining matrices of identity-by-descent allele-sharing.
THE FRAMINGHAM HEART STUDY DATA
The data set for Problem 1 came from the Framingham Heart Study, centered in Framingham, Massachusetts. The Framingham Heart Study is an ongoing prospective study of risk factors for cardiovascular disease. The GAW13 data set consisted of genotyping information from a 10-cM genome scan, along with phenotypic information.
Originating in 1948, the Framingham Heart Study (under the direction of the National Heart Institute, now known as the National Heart, Lung, and Blood Institute, or NHLBI) embarked on an ambitious project in health research. At the time, little was known about the underlying causes of heart disease and stroke, but the death rates for cardiovascular disease (CVD) had been increasing steadily since the beginning of the 20th century and had become an American epidemic. Despite declines in the latter part of the century, cardiovascular disease remains the top cause of death in the US today. The Framingham Heart Study is now conducted in collaboration with Boston University.
The objective of the Framingham Heart Study was to identify common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke [Dawber, 1980] . The study was one of the first long-term prospective studies, and was planned for 20 years initially. It continues today with more than 50 years of follow-up on the Original Cohort.
Framingham, Massachusetts was selected because it was a moderate-sized town with a relatively stable population that was thought to reflect many communities in the US at that time. In the late 1940s it was estimated that about 10,000 individuals were in the age range 30-60 years in this community, and thus were eligible for recruitment into a study of approximately 6,000 subjects. The researchers recruited 5,209 subjects (2,336 men and 2,873 women) between ages 28-62 from a systematic 2/3 sample of the households in the town. The plan was to recruit all household members in the age range of 30-60 years within each house that was selected for study. Thus, the sample included 1,644 spouse pairs. Although there was no intention to recruit extended families for family studies, many biologically related individuals were recruited, including siblings and some parent-offspring pairs. Since 1948, members of the Original Cohort have continued to return to the study every 2 years for a detailed medical history, physical examination, and laboratory tests.
The study enrolled a second-generation (5,124 of the original participants' adult children and the spouses of these adult children) to participate in similar examinations in 1971. Two thousand six hundred and sixteen of these subjects are offspring of the spouse pairs from the Original Cohort, and 34 are stepchildren. Another 898 offspring are children of cohort members where only one parent was a study participant; they were recruited because their parents exhibited elevated lipid levels. In addition, 1,576 Offspring Cohort participants are spouses of offspring. The Offspring Cohort has been followed every 4 years (except between Exams 1 and 2 with an intervening 8 years), using protocols similar to those used for study of the Original Cohort. A third cohort is currently being recruited.
In the mid-1990s, about 1,800 members of the largest 330 pedigrees were selected for a 10-cM genome scan that was conducted by the Mammalian Genotyping Service in Marshfield, Wisconsin. The expanded pedigrees consist of 4,692 subjects, of whom 2,885 participated in the Framingham Heart Study. Among the Framingham participants in these 330 pedigrees, there are 3,041 parent-offspring pairs, 2,796 sibpairs, 2,107 avuncular pairs, 183 grandparent-grandchild pairs, and 1,595 first-cousin pairs.
For GAW13, data were provided for systolic blood pressure, height, weight, total cholesterol, fasting, high density lipoprotein (HDL) cholesterol and triglycerides, blood glucose, and appropriate covariates such as age, sex, smoking, and alcohol consumption. These data were made available for study participants in the 330 genotyped pedigrees from the Original and the Offspring Cohorts and covered the first 40 years of follow-up in the Original Cohort (Exams 1-21) and the first 20 years of follow-up in the Offspring Cohort (Exams 1-5).
While pursuing the Study's established research goals, the NHLBI and the Framingham investigators are expanding their research into other areas, such as the role of genetic factors in CVD. One project currently underway is the establishment of immortalized cell lines from surviving Original Cohort participants and members of the Offspring Cohort. These cell lines will enable extensive investigation of the genetic etiology of not only CVD, but also other diseases. Framingham investigators also collaborate with leading researchers from around the country and throughout the world on projects in stroke and dementia, osteoporosis and arthritis, nutrition, diabetes, eye diseases, hearing disorders, lung diseases, and genetic patterns of common diseases.
A full description of the GAW13 Framingham Heart Study data set is provided by Cupples et al. [2003] , and further information about the Framingham Heart Study can be found at http:// www.nhlbi.nih.gov/about/framingham/index. html. The Study invites researchers around the world to consider this rare collection of data as a resource that may further their own research. There are established protocols for requesting data and/or DNA samples, and investigators are encouraged to pursue research questions using this resource.
THE SIMULATED DATA
The simulated data set for GAW 13 was modeled after the real Framingham Heart Study data. This stands in contrast to previous GAWs, where the different data sets available were unrelated. For each variable available in the Framingham Heart Study data, a variable was simulated with a similar distribution to that in the real data. These simulated variables were designed with relationships guided by correlations observed in the Framingham Heart Study data. Like the Framingham Heart Study data, the simulated data were longitudinal, and changes in value over time in the simulated set were guided by trends observed in the Framingham Heart Study data. However, while consideration was given to observations from the Framingham Heart Study data and the advice of biologists, the primary concern in designing the simulated data was to provide a variety of different types of effects on which to test analysis methods. Exactly modeling the unknown biological mechanisms underlying these traits is an impossible goal and was not attempted.
The simulated trait model was complex, with 50 trait loci acting on a system of eight quantitative traits with effects due to sex, a treatment variable, and two ''environmental'' variables. Death was simulated with a liability model, and there was also one qualitative diagnosis, hypertension. For each individual, simulated data values were generated at 1-year intervals starting at age 20. These ''complete'' simulated data were then sampled, via a ascertainment/missing data process, to obtain two cohorts, as in the Framingham Heart Study data. Data collection on each cohort started about 30 years apart. As with the real data, the first cohort was examined 21 times at 2-year intervals, while the second was examined 5 times with an 8-year interval between the first two exams and 4 years between subsequent exams.
The full trait simulation model is described in detail in [Daw et al., 2003 ], so we will only describe it in brief here. The eight simulated quantitative traits upon which genes acted directly were: height, weight, HDL, triglycerides, glucose, cholesterol, systolic blood pressure, and diastolic blood pressure. Some of the genetic effects were large, accounting for up to 40% of trait variance, while others were small, accounting for 1% or less of trait variance. The goal in providing a wide range of effect sizes was to help determine the limits of resolution of various methods. It was not expected that the smallest effects could be detected. The trait loci were divided into those that affected the baseline value (baseline genes), and those that affected change in value over time (slope genes). All eight traits had baseline genes, but height and HDL had no slope genes. The trait loci were simulated with a genome screen of 399 microsatellite markers on 22 autosomal chromosomes. Trait loci were placed on odd-numbered chromosomes only, leaving the even-numbered chromosomes available for studies of false-positive rates. The marker and trait loci were generated by random gene-drop, using a sex-specific meiotic map. The trait gene locations were the same in all 100 replicates of the simulated data.
Several variables were simulated with no direct genetic effect. Drinking and smoking were simulated as environmental variables, with effects from birth-year, parental smoking habits, and sex. Hypertension diagnosis was made on the basis of elevated systolic or diastolic blood pressure levels. Treatment for hypertension was simulated, with changing treatments available over time. Death was simulated as a liability function with effects of smoking, systolic blood pressure, and cholesterol.
Longitudinal studies present a more serious problem with missing data than do cross-sectional studies, because few subjects will have complete observations at all time points. Additionally, the pattern of missing data could be informative in the sense that it may depend on measured or unmeasured phenotypes of interest, such as quantitative risk factors or death, and may be correlated among family members. Although this has been an active area of research in other branches of statistics, little attention has been paid to the problem of missingness that can depend on both temporal and familial factors. As in the simulation of trait models, the simulation of missing data patterns was based on the factors found to be correlated with missingness in the real Framingham Heart Study data.
